GBLT Establishes a Partnership with a Multi-Billion Dollar Pharmaceutical Distribution for Global Expansion
TORONTO and DUREN, Germany, Aug. 9, 2023 /CNW/ - GBLT Corp. (TSXV: GBLT) ("GBLT" or the "Company") is pleased to announce that it has entered into a partnership to provide the Company's Dr. Senst personal healthcare products to a major pharmaceutical distributor ("Distributor") with over 3,200 retail pharmacies and 224 business sites in 29 countries.
"We are pleased to announce the new vendor relationship with the multi-billion dollar leader in pharmaceutical distribution for our Dr. Sensts' healthcare products," said Dr. Thilo Senst, CEO of GBLT. "This new relationship with the Distributor with access to both wholesale and retail divisions in over 29 countries is a prime example of how multi-national corporations continue to trust our Company and our quality product lines as we continue to win new and expand existing partnership deals in 2023. We are excited to commence delivering our high-margin healthcare products and providing future opportunities to expand our offerings and scale our partnership further."
Dr. Senst continued, "We are confident in the distribution relationship established with the multi-national pharmaceutical distributor will be the key to creating new revenue opportunities and further diversify our offerings across different countries and are excited for the opportunity. As part of our core corporate strategy, we have continued to focus our efforts for the first half of the year on expansionary efforts in order to diversify our revenue channels and establish a strong foundation to finish the second half of the year strong with new established revenue streams and bottom line growth."
GBLT Corp., through its operating company, GBT GmbH, designs, manufactures and supplies mobile storage, and battery solutions. GBLT is also a leading provider of renewable energy solutions via its solar division, participating in the rapidly growing solar energy market. In addition, the Company offers consumer healthcare and wellness products to some of the largest retail chains across the globe. GBT is also an official licensee for AGFAPHOTO mobile energy products. The Company's branded healthcare and wellbeing products are primarily sold throughout Europe under Dr. Senst brand.
For more information, please visit www.gbt-international.com and www.gbltcorp.com.
Certain statements in this news release, which are not historical in nature, constitute "forward looking statements" within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company's proposed activities under the Agreement, the Company's ability to achieve sales, commercial or otherwise, from its products, and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management's current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE GBLT Corp.
GBLT Corp., Dr. Thilo Senst, CEO, Tel.: +49(0)2421-20856-0, Email: [email protected]; Investor Relations: Virtus Advisory Group, Tel: 416-646-6779, Email : [email protected]
Share this article